T. Rowe Price Investment Management Inc. Decreases Stock Holdings in Sotera Health (NASDAQ:SHC)

T. Rowe Price Investment Management Inc. lowered its holdings in Sotera Health (NASDAQ:SHC) by 19.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,594,741 shares of the company’s stock after selling 1,823,250 shares during the period. T. Rowe Price Investment Management Inc.’s holdings in Sotera Health were worth $103,897,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Blue Trust Inc. boosted its position in Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock worth $25,000 after purchasing an additional 1,140 shares during the period. GAMMA Investing LLC lifted its stake in shares of Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after purchasing an additional 1,121 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company’s stock worth $82,000 after buying an additional 1,640 shares during the period. Sterling Capital Management LLC grew its stake in shares of Sotera Health by 58.5% in the fourth quarter. Sterling Capital Management LLC now owns 9,029 shares of the company’s stock valued at $124,000 after buying an additional 3,331 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Sotera Health by 39.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,302 shares of the company’s stock valued at $127,000 after buying an additional 2,627 shares during the period. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Barclays decreased their price target on Sotera Health from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Piper Sandler decreased their target price on shares of Sotera Health from $15.00 to $13.00 and set a “neutral” rating for the company in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.20.

Sotera Health Stock Performance

Shares of SHC opened at $11.30 on Friday. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of 45.20 and a beta of 1.88. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The business’s 50 day moving average is $11.61 and its two-hundred day moving average is $13.20. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.